MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock under the...
$57,880K
Proceeds from exercise of
employee stock options...
$151K
Net cash provided by
(used in) financing...
$57,781K
Canceled cashflow
$250K
Net increase in cash
and cash...
$8,700K
Canceled cashflow
$49,081K
Payments of employee
withholding taxes related to...
$250K
Proceeds from sales and
maturities of marketable...
$20,750K
Stock-based compensation
expense
$3,198K
Accounts payable
$1,513K
Accounts receivable,
prepaid expenses and...
-$742K
Depreciation and
amortization
$102K
Net cash (used in)
provided by investing...
-$30,932K
Net cash used in
operating activities
-$18,149K
Canceled cashflow
$20,750K
Canceled cashflow
$5,555K
Purchases of marketable
securities
$51,669K
Net loss
-$19,824K
Purchases of property and
equipment
$13K
Accrued expenses and
other liabilities
-$3,026K
Deferred income
-$854K
Back
Back
Cash Flow
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)
source: myfinsight.com